Product logins

Find logins to all Clarivate products below.


Urological Devices | Market Insights | Asia Pacific (Supplemental) | 2021

Despite the impact of the ongoing COVID-19 pandemic, the Asia Pacific urological device market will continue to expand through 2029 due to growing patient awareness of urological treatments in this region. In particular, rising use of minimally invasive laser treatments for urinary stones and BPH will drive sales in several segments of this market, thus fueling overall market growth. However, the market will be negatively affected in the short term by the global COVID-19 pandemic.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for urological devices in the Asia Pacific region across a 10-year period.

Related Medtech Insights Reports

Report
Cardiac Rhythm Management Devices – Market Insights – Asia Pacific
The Asia Pacific CRM device market will register modest growth over the forecast period. Key growth drivers include the rising adoption of premium-priced technologies such as CRT devices, leadless…
Report
Aortic Repair Devices – Market Insights – Asia Pacific
The Asia Pacific aortic repair device market is projected to experience robust growth during the forecast period, fueled by rising endovascular procedure volumes, ongoing innovation in aortic stent…
Report
Cardiac Rhythm Management Devices | Market Insights | Asia Pacific (Supplemental) | 2025
The Asia Pacific CRM device market will experience modest growth over the forecast period, driven primarily by the increasing volume of ICM procedures and the adoption of premium-priced devices,…
Report
Urological Devices – Market Insights – Latin America
The Latin American urological device market will continue to expand through 2034, driven by the rising prevalence of kidney stones and UI, aging populations, and growing patient awareness of…
Report
Biosurgical Agents – Market Insights – Asia Pacific
The biosurgical agent market in Asia Pacific will experience modest growth through 2034, driven by rising surgical procedure volumes and expanding use of biosurgical agents across a broader range…